Celecoxib: A review of its use in osteoarthritis, rheumatoid arthritis and acute pain

Drugs

Volumn 59, Issue 4, 2000, Pages 957-980

  Clemett, Delyth ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOCHROME P450; DICLOFENAC; HYDROCODONE; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROSTAGLANDIN E2; PROSTAGLANDIN F1 ALPHA; SODIUM; THROMBOXANE B2; WARFARIN;

ABDOMINAL PAIN; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG TOLERABILITY; DUODENUM ULCER; HUMAN; MULTICENTER STUDY; NONHUMAN; OSTEOARTHRITIS; PAIN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; STOMACH MUCOSA LESION; STOMACH ULCER;

EID: 0034093534     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059040-00017     Document Type: Review

References (103)

1. 1. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 240 (24): 1888-99
2. 2. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998; 105(1B): 31S-8S
3. 3. Langman MJS, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075-8
4. 4. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991; 115: 787-96
5. 5. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971; 231 (25): 232-5
6. 2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990; 265 (28): 16737-40
7. 7. Xie WL, Chipman JG, Robertson DL, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRN A splicing. Proc Natl Acad Sci U S A 1991; 88 (7): 2692-6
8. 8. Needleman P, Isakson PC. The discovery and function of COX-2. J Rheumatol 1997; 24 Suppl. 49: 6-8
9. 9. Masferrer JL, Zweifel BS, Manning PT, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci U S A 1994; 91: 3228-32
10. 10. Seibert K, Zhang Y, Leahy K, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci U S A 1994; 91: 12013-7
11. 11. Vane JR, Mitchell JA, Appleton I, et al. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci U S A 1994; 91 (6): 2046-50
12. 12. Gierse JK, Hauser SD, Creely DP, et al. Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J 1995; 305: 479-84
13. 13. Laneuville O, Breuer DK, Dewitt DL, et al. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 1994; 271 (2): 927-34
14. 14. Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol 1997; 24 Suppl. 49: 15-9
15. 15. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104 (3 A): 2S-8S
16. 16. GD Searle and Company. Celecoxib prescribing information. Skokie, Illinois, 1999, Dec 23
17. 17. Lipsky PE, Abramson SB, Crofford L, et al. The classification of cyclooxygenase inhibitors. J Rheumatol 1998; 25 (12): 2298-302
18. 18. Penning TD, Talley JJ, Bertenshaw SR, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzene-sulfonamide (SC-58635, celecoxib). J Med Chem 1997; 40: 1347-65
19. 19. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999; 96: 272-7
20. 20. Smith CJ, Zhang Y, Koboldt CM, et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A 1998; 95: 13313-8
21. 21. Maziasz T, Seibert K, Khan N, et al. Preclinical pharmacology of celecoxib and demonstration of superior GI safety compared with NSAIDs in dogs [abstract]. Arthritis Rheum 1997; 40 Suppl.: S195
22. 22. Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safely in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998; 41: 1591-602
23. 23. Schafer AI. Effects of nonsteroidal anti-inflammatory therapy on platelets. Am J Med 1999; 106 Suppl. 5B: 25S-35S
24. 24. Geis GS, FitzGerald G, Karim A, et al. A comparative study of platelet function in subjects receiving either celecoxib, a specific COX-2 inhibitor, or ibuprofen, a nonspecific inhibitor of cyclooxygenase [abstract]. Ann Rheum Dis 1999: 205
25. 25. Leese PT, Hubbard RC, Karim A, et al. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 2000; 40: 124-32
26. 26. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999; 106 Suppl. 5B: 13S-24S
27. 27. Whelton A, Schulman G, Wallenmark C, et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000. In press
28. 28. Mengle-Gaw L, Hubbard RC, Karim A, et al. A study of the platelet effects of SC-58635, a novel COX-2 selective inhibitor [abstract]. Arthritis Rheum 1997; 40 Suppl.: S93
29. 29. Paulson SK, Kaprak TA, Gresk CJ et al. Plasma protein binding of celecoxib in mice, rat, rabbit, dog and human. Biopharm Drug Dispos 1999; 20: 293-9
30. 30. Karim A, Tolbert D, Burton E, et al. SC-58635 (Celecoxib): a highly selective inhibitor of cyclooxygenase-2. Disposition kinetics in man and identification of its major CYP450 isozyme in its biotransformation [abstract]. Pharm Res 1997; 14 Suppl.: 617
31. 14C]celecoxib in healthy male volunteers. Drug Metab Dispos 2000; 28: 308-14
32. 32. Karim A, Piergies A, Tolbert D, et al. Selective inhibitor of cyclo-oxygenase-2 (COX-2), SC-58635 (Celecoxib), does not affect kinetics or dynamics of warfarin [abstract]. J Clin Pharmacol 1998; 38: 880
33. 33. Searle/Pfizer. Health Care Professional letter [online]. Available from http://www.fda.gov/medwatch/safety/1999/ celebr.htm. Accessed 10 Jan 2000
34. 34. Karim A, Tolbert DS, Hunt TL, et al. Celecoxib, a specific COX-2 inhibitor, has no significant effects on methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol 1999; 26 (12): 2539-43
35. 35. Semla TP, Piergies AA, Bradford D, et al. Steady-state drug-drug interaction assessment between celecoxib and methyl-phenidate [abstract]. Pharmacotherapy 1999; 19: 1218
36. 36. Bensen WG, Fiechtner JJ, McMillen JI, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999; 74: 1095-105
37. 37. Hubbard RC, Geis GS, Woods EM, et al. Efficacy and tolerability of celecoxib, a COX-2 specific inhibitor, for treating the pain and inflammation of osteoarthritis. Proceedings of the 18th Annual Meeting of the American Pain Society, 1999 Oct 21-24; Fort Lauderdale (FL), 613
38. 38. Williams GW, Ettlinger RE, Ruderman EM, et al. Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib: a randomized, controlled trial. Clin Rheumatol 2000. In press
39. 39. Geis GS, Hubbard RC, Yu S, et al. Efficacy and tolerabilily of celecoxib: a comparison of once-daily vs twice-daily dosing [abstract]. Arthritis Rheum, 1999; 42 Suppl.: 144
40. 40. Zhao SZ, McMillen JI, Markenson JA, et al. Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib. Pharmacotherapy 1999; 19: 1269-78
41. 41. Zhao SZ, Dedhiya SD, Verburg K, et al. Celecoxib 200mg administered once-a-day or in split doses has equal impact on health-related quality of life (HRQOL) of patients with osteoarthritis (OA) [abstract]. Arthritis Rheum 1999; 42 Suppl.: 297
42. 42. Geis GS, Hubbard RC, Woods EM, et al. Efficacy of celecoxib, a COX-2 specific inhibitor, in osteoarthritis of the hip [abstract]. Arthritis Rheum 1999; 42 Suppl.: 144
43. 43. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999; 282: 1921-8
44. 44. Geis GS, Hubbard HC, Woods EM, et al. Efficacy and safety of celecoxib, a specific cyclooxygenase-2 inhibitor, in rheumatoid arthritis [abstract]. Ann Rheum Dis 1999: 205
45. 45. Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999; 354: 2106-11
46. 46. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Arthritis Rheum 1986; 29 (8): 1039-49
47. 47. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24
48. 48. Hochberg MC, Chang RW, Dwosh I, et al. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992; 35: 498-502
49. 49. Hubbard RC, Mehlisch DR, Jasper DR, et al. SC-58635, a highly selective inhibitor of COX-2, is an effective analgesic in an acute post-surgical pain model [abstract]. J Invest Med 1996; 44: 293A
50. 50. Malmstrom K, Daniels S, Kotey P, et al. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors in postoperative dental pain: a randomized, placebo-and active-comparator-controlled clinical trial. Clin Ther 1999; 21: 1653-63
51. 51. Brugger AM, Richardson ET, Drupka DT, et al. Comparison of celecoxib, hydrocodone/acetaminophen, and placebo for relief of post-surgical pain. 18th Ann Sci Meet Am Pain Soc 1999 Oct 21
52. 52. American Pain Society Quality of Care Committee. Quality improvement guidelines for the treatment of acute pain and cancer pain. JAMA 1995; 274: 1874-80
53. 53. Moskowitz R, Sunshine A, Woods E, et al. Efficacy of celecoxib in treating acute flare pain in osteoarthritis of the knee [abstract]. Proceedings of the 9th World Congress on Pain, 1999 Aug 22-27; Vienna, 245
54. 54. Geis GS, Hubbard RC, Woods EM, et al. Efficacy of celecoxib for relief of pain in osteoarthritis of the hip. Proceedings of the Annual Meeting of the American Pain Society, 1999 Oct 21-24, Fort Lauderdale (FL), 1999: 612
55. 55. Sunshine A, Moskowitz R, Woods E, et al. Efficacy of celecoxib in treating acute flare pain in osteoarthritis of the hip. Proceedings of the 9th World Congress on Pain, 1999 Aug 22-27; Vienna, 248
56. 56. Zhao SZ, Dedhiya SD, Verburg K, et al. Celecoxib improves health related quality of life of elderly patients with osteoarthritis [abstract]. Arthritis Rheum 1999; 42 Suppl.: 296
57. 57. Zhao SZ, Yu SS, Dedhiya SD, et al. Celecoxib improves health-related quality of life in patients with osteoarthritis of the knee [abstract]. Pharmacotherapy 1999; 19: 495
58. 58. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35
59. 59. Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986; 25: 206-9
60. 60. Zhao ZS, Yu SS, Zhao WW, et al. Celecoxib improves ability to perform daily activities in patients with rheumatoid arthritis [abstract]. Ann Rheum Dis 1999: 203
61. 61. Zhao SZ, Yu SS, Dedhiya SD, et al. Celecoxib improves health-related quality of life in patients with rheumatoid arthritis [abstract]. Pharmacotherapy 1999; 19: 497
62. 62. Merck & Co. Rofecoxib prescribing information. Whitehouse Station, NJ, 1999. Sep
63. 63. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced ulcer damage with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 1988; (8632): 1277-80
64. 64. Lanza FL. Gastrointestinal toxicity of newer NSAIDs. Am J Gastroenterol 1993; 88: 1318-23
65. 65. Paulus HE. FDA Arthritis Advisory Committee meeting: postmarketing surveillance of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1985; 28: 1168-9
66. 66. CSM update. Non-steroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions. BMJ 1986; 292: 1190-1
67. 67. Graham DY, Smith JL. Aspirin and the stomach. Ann Intern Med 1986; 104: 390-8
68. 68. Larkai EN, Smith JL, Lidsky MD, et al. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987; 82: 363-4
69. 69. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999; 26 Suppl. 56: 18-24
70. 70. Lichtenstein DR, Syngal S, Wolfe MM. Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract. The double-edged sword. Arthritis Rheum 1995; 38: 5-18
71. 71. Anon. Searle will conduct phase IV Celebrex study to establish GI effects claim. FDC Blue 1999 Jan 6; 42: 3-4
72. 72. British National Formulary, vol 38. Derby: British Medical Association, 1999 Sep
73. 73. Goldstein JL, Silverstein FE, Agrawal NM, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol. In press
74. 74. Singh G, Ramey DR, Triadafilopoulos G. Early experience with selective COX-2 inhibitors: safety profile in over 340,000 patient years of use [abstract]. Arthritis Rheumatism 1999: 296
75. 75. Patterson R, Bello AE, Lefkowith J. Immunologic tolerability profile of celecoxib. Clin Ther 1999; 21: 2065-79
76. 76. Bensen WG, Zhao SZ, Burke TA, et al. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. J Rheumatol. In press
77. 77. Anon. Searle warns on Celebrex interaction. Scrip 1999 Jun 2-4 (2442-2443): 23
78. 78. Gupta S, McCune WJ, Kaplan MJ, et al. Thrombosis and ischemia in patients with systemic lupus erythematosus treated with celecoxib: a series of two cases [abstract]. Arthritis Rheum 1999; 42 Suppl.: 149
79. 79. Whelton A, Maurath CJ, Verburg KM, et al. Renal safety and tolerability of celecoxib, a novel cyclooxygenase (COX)-2 inhibitor. Am J Ther 2000 (In press)
80. 80. Maddrey WC, Maurath CJ, Verburg KM, et al. The hepatic safety and tolerability of the novel cyclooxygcnase (COX)-2 inhibitor celecoxib. Am J Ther 2000 (In press)
81. 81. Centers for Disease Control and Prevention. Current trends prevalence of disabilities and associated health conditions -United States, 1991-1992. MMWR 1994; 43 (40): 730-1
82. 82. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41 (5): 778-99
83. 83. Lipsky PE. Rheumatoid arthritis. In: Fauci AS, Braunwald E, Isselbacher KJ, editors. Harrison's principles of internal medicine. 14th ed. v. 2. New York: McGraw-Hill, 1998: 1880-8
84. 84. Brandt KD. Osteoarthritis. In: Fauci AS, Braunwald E, Isselbacher KJ, editors. Harrison's principles of internal medicine. 14th ed. v. 2. NEw York: McGraw-Hill, 1998: 1935-41
85. 85. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. Arthritis Rheum 1995; 38: 1535-40
86. 86. Hochherg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. Arthritis Rheum 1995; 38: 1541-6
87. 87. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996; 39 (5): 713-22
88. 88. Roth SH. NSAID gastropathy: a new understanding. Arch Intern Med 1996; 156: 1623-8
89. 89. Wilcox MC, Shalek KA, Cotsonis G. Striking prevalence of over-the-counter nonsteroidal anti-inflammatory drug use in patients with upper gastrointestinal hemorrhage. Arch Intern Med 1994; 154: 42-6
90. 90. Fries JF, Miller SR, Spitz PW, et al. Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastraenterology 1989; 96 Suppl. 2 (Pt 2): 647-55
91. 91. Blower AL, Brooks A, Fenn GC, et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 1997; 11: 283-91
92. 92. Bolten WW, Lang B, Wagner AV, et al. Consequences and costs of NSAID gastropathy in Germany [in German]. Aktuel Rheumatol 1999; 24: 127-134
93. 93. Raskin JB. Gastrointestinal effects of nonsteroidal anti-inflammatory therapy. Am J Med 1999; 106 Suppl. 5B: 3S-12S
94. 94. Bolten WW. Scientific rationale for specific inhibition of COX-2. J Rheumatol 1998; 25 Suppl. 51: 2-7
95. 95. Geis GS. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect? J Rheumatol 1999; 26 Suppl. 56: 31-6
96. 96. Anon. Celebrex acute pain claim limited to dental surgery could be considered. FDC Rep Pink Sheet 1998 Dec 7; 60: 5
97. 97. Anon. Celecoxib approved as NSAID with some concessions on class warning. Am J Health System Pharm 1999; 56: 403
98. 98. Singh G, Ramey DR, Morfeld D, et al. Gastrointestinal tract complications on nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: a prospective observational cohort study. Arch Intern Med 1996; 156: 1530-6
99. 99. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life-threatening complications of peptic ulceration. Gut 1987; 28: 528-32
100. 100. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 769-72
101. 101. Fries JF, Williams CA, Bloch DA, et al. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991; 91: 213-22
102. 102. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114: 257-63
103. 103. Piper JM, Ray WA, Daugherty JR. et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114: 735-40